Many standard of care (SOC) treatments in cancer patients result in a clinical outcome of non-response. Drug development companies are trending toward interrogating resistance mechanisms and using this information in advancing their programs and informing personalized approaches to novel therapeutics.
In this free webinar, learn about:
- Key ingredients to testing hypotheses of specific resistance mechanisms that are involved in non-responders in a specific case study
- How various drug combinations may overcome these identified resistance mechanisms
- Discussion on how to improve clinical trial design
This webinar will benefit executives in small to mid-size biotech and pharmaceutical companies interested in learning more about how to save time and money while maximizing the value of their drug development clinical trial programs.
Dr. Mark Paris, Director of Translational Applications, Mitra Biotech
Dr. Mark Paris works with clients to customize studies for their drug development needs. He spent 16 years in commercial antibody discovery and clinical development focusing on immuno-oncology. Molecules discovered and developed under his direction are currently in Phase 2 clinical trials. Dr. Paris is a graduate of Case Western Reserve University with a PhD in Genetics, and a former fellow in the department of Cancer Biology at the Cleveland Clinic Foundation.Message Presenter
Who Should Attend?
Oncology program translational leads working with small molecules, biologics, and I/O drug candidates.
What You Will Learn
Attendees will explore:
- Market landscape of companies using resistance mechanisms in drug development processes
- Most up-to-date strategies to interrogate drug resistance patterns in non-responders
- Methods to systematically test your hypothesis on how to overcome drug resistance patterns
Mitra Biotech Inc
Mitra Biotech Inc. is a global leader in advancing truly personalized oncology treatment. The company’s CANscript™ platform recreates a patient’s own tumor microenvironment in vitro, measures multiple parameters to determine whether a tumor is responding to customer selected treatments, and then converts these parameters into a single score that predicts clinical response to each of the customer selected therapies.
CANscript delivers powerful, individualized treatment response predictions — with exceptionally high correlation to clinical outcomes — to inform patient-specific cancer treatment selection and support more effective and efficient cancer drug development.
Founded in 2010, Mitra is headquartered in Greater Boston and maintains a significant research and laboratory presence in Bengaluru, India.